BlackRock Fund Advisors’s Larimar Therapeutics LRMR Stock Holding History

BlackRock Fund Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.32M	Sell	60,774 -22,998	-27%	-$933K	﹤0.01%	3137
2016 Q3	$3.33M	Buy	83,772 +6,308	+8%	+$286K	﹤0.01%	3034
2016 Q2	$5.57M	Buy	77,464 +11,973	+18%	+$946K	﹤0.01%	2733
2016 Q1	$5.25M	Buy	65,491 +2,619	+4%	+$207K	﹤0.01%	2721
2015 Q4	$4.75M	Sell	62,872 -4,996	-7%	-$803K	﹤0.01%	2864
2015 Q3	$26M	Buy	67,868 +2,772	+4%	+$1.25M	0.01%	1829
2015 Q2	$27.1M	Buy	65,096 +19,188	+42%	+$8.03M	0.01%	1924
2015 Q1	$21.8M	Buy	45,908 +7,737	+20%	+$3.67M	0.01%	2022
2014 Q4	$14.1M	Buy	38,171 +24,012	+170%	+$6.19M	﹤0.01%	2249
2014 Q3	$3.34M	Buy	+14,159	New	+$3.21M	﹤0.01%	2974

Other funds holding LRMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock Fund Advisors's LRMR Position: Q4 2016 in Review

BlackRock Fund Advisors reduced its Larimar Therapeutics (LRMR) stake by 27% in Q4 2016, selling an estimated $933K and leaving 60,774 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3137.

BlackRock Fund Advisors first reported a position in LRMR in Q3 2014 and has held it in 10 quarters since. The position peaked at $27.1M in Q2 2015. 81 funds tracked by Wall St. Rank hold LRMR as of Q4 2016.

BlackRock Fund Advisors held 60,774 shares of Larimar Therapeutics worth $2.32M as of Q4 2016.
BlackRock Fund Advisors sold 22,998 Larimar Therapeutics shares in Q4 2016, an estimated $933K.
Larimar Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3137 holding.
BlackRock Fund Advisors first reported a position in Larimar Therapeutics in Q3 2014 and has held it in 10 quarters since.
BlackRock Fund Advisors's Larimar Therapeutics position peaked at $27.1M in Q2 2015.
81 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.